Take real world issues into account

Pink and colleagues’ analysis of the economics of dabigatran is flawed by several real world issues that were not considered.1 Firstly, the price of dabigatran will fall as competitive drugs are licensed. Secondly, the cost of stopping international normalised ratio (INR) monitoring depends on whether warfarin clinics continue to run but …